Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
2255 articles about Gilead Sciences, Inc.
-
Gilead Sciences, Inc. Bumps Up Filing Timeline for Quad Pill, HIV Med Outperforms Rival in Study
9/21/2011
-
Gilead Sciences, Inc. to Present at the UBS Global Life Sciences Conference on Tuesday, September 20
9/20/2011
-
New AHF Ad Exposes Gilead Sciences, Inc. on HIV Prevention Pill
9/15/2011
-
High Hopes for Gilead Sciences, Inc.'s "Quad" Studies as Company Eyes Foster City Expansion
9/12/2011
-
Gilead Sciences, Inc. Amends Study Design for Ongoing Hepatitis C Clinical Trials That Include GS 9190, Pegylated Interferon and Ribavirin, and Another Direct-Acting Antiviral Agent
9/6/2011
-
Gilead Sciences, Inc. to Present at Baird's 2011 Health Care Conference on Thursday, September 8
9/1/2011
-
AHF Spearheads "Pill Bottle Protest" Over Gilead's AIDS Drug Prices
9/1/2011
-
Lancet Concerned that Gilead Sciences, Inc.'s Truvada as PrEP Will Encourage High-Risk Sex, Says AHF
8/25/2011
-
Gilead Sciences, Inc. PrEP Campaign Leads to Truvada Black Market in Florida, AHF Says
8/19/2011
-
Gilead Sciences, Inc. Chases More Deals, Re-enters Cancer Medicines Market by Developing Combo Cancer Drugs
8/16/2011
-
Gilead Sciences, Inc.'s Quad JOV Drug Shows Positive Results in Phase III Trial
8/15/2011
-
FDA Approves Gilead Sciences, Inc.'s Once-Daily HIV Treatment Complera
8/12/2011
-
AHF: Gilead Sciences, Inc.'s Pricing of Complera May Break Hard-Hit AIDS Drug Programs
8/12/2011
-
Gilead Sciences, Inc. Addresses FDA's Manufacturing Concerns at California Facility
8/11/2011
-
Gilead Sciences, Inc. to Purchase Biologics Plant From Genentech
8/9/2011
-
MPP-Gilead Sciences, Inc. Deal is Not a Template: Childs Explains
8/3/2011
-
Gilead Sciences, Inc.’s Investigational Antiretroviral Elvitegravir Once Daily Non-Inferior to Raltegravir Twice Daily at 48 Weeks
7/20/2011
-
Gilead Sciences, Inc. to Release Second Quarter 2011 Financial Results on Tuesday, July 26, 2011
7/20/2011
-
Gilead Sciences, Inc. Kickstarts Patent Pool for AIDS Drugs, Agrees to Let Generic Companies like Mylan Inc., Ranbaxy Laboratories Make Them
7/12/2011
-
Doctors to FDA: Gilead Sciences, Inc.'s "HIV Prevention Pill" Not Ready for Approval
6/30/2011